Neutralizing Antibodies Against Interferon-Beta in Korean Patients with Multiple Sclerosis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Patients treated with interferon-beta (IFN-β) can develop neutralizingantibodies (NAbs) against IFN-β that can negatively affect the therapeutic response. This study assessed the prevalence of NAbs and the impact of NAb positivity on the therapeuticresponse to IFN-β in Korean patients with multiple sclerosis (MS). Methods This was a multicenter study involving 150 MS patients from 9 Korean medicalcenters who were treated with IFN-β for at least 6 months. Sera that had not been influencedby acute treatment were assessed for NAbs using a luciferase reporter gene assay. To evaluatethe association between persistent positivity for NAbs and disease activity, NAbs were tested at2 different time points in 75 of the 150 patients. Disease activity was defined as the presence ofclinical exacerbations and/or active MRI lesions during a 1-year follow-up after NAb positivitywas confirmed. Results NAbs were found in 39 of the 150 (26%) MS patients: 30 of the 85 (35%) who weretreated with subcutaneous IFN-β-1b, 9 of the 60 (15%) who were treated with subcutaneousIFN-β-1a, and 0 of the 5 (0%) who were treated with intramuscular IFN-β-1a. Thirty of the 39patients exhibiting NAb positivity were tested at different time points, and 20 of them exhibitedpersistent NAb positivity. Disease activity was observed more frequently in patients with persistentNAb positivity than in those with transient positivity or persistent negativity [16/20 (80%)vs. 4/55 (7%), respectively; p<0.001]. When disease activity was compared between patientswith persistent and transient NAb positivity, the difference was unchanged and remained statisticallysignificant [16/20 (80%) vs. 2/10 (20%), p=0.004]. Conclusions These results further support that persistent NAb positivity is associated withdisease activity in MS patients treated with IFN-β.
Abstract
Background and Purpose Patients treated with interferon-beta (IFN-β) can develop neutralizingantibodies (NAbs) against IFN-β that can negatively affect the therapeutic response. This study assessed the prevalence of NAbs and the impact of NAb positivity on the therapeuticresponse to IFN-β in Korean patients with multiple sclerosis (MS). Methods This was a multicenter study involving 150 MS patients from 9 Korean medicalcenters who were treated with IFN-β for at least 6 months. Sera that had not been influencedby acute treatment were assessed for NAbs using a luciferase reporter gene assay. To evaluatethe association between persistent positivity for NAbs and disease activity, NAbs were tested at2 different time points in 75 of the 150 patients. Disease activity was defined as the presence ofclinical exacerbations and/or active MRI lesions during a 1-year follow-up after NAb positivitywas confirmed. Results NAbs were found in 39 of the 150 (26%) MS patients: 30 of the 85 (35%) who weretreated with subcutaneous IFN-β-1b, 9 of the 60 (15%) who were treated with subcutaneousIFN-β-1a, and 0 of the 5 (0%) who were treated with intramuscular IFN-β-1a. Thirty of the 39patients exhibiting NAb positivity were tested at different time points, and 20 of them exhibitedpersistent NAb positivity. Disease activity was observed more frequently in patients with persistentNAb positivity than in those with transient positivity or persistent negativity [16/20 (80%)vs. 4/55 (7%), respectively; p<0.001]. When disease activity was compared between patientswith persistent and transient NAb positivity, the difference was unchanged and remained statisticallysignificant [16/20 (80%) vs. 2/10 (20%), p=0.004]. Conclusions These results further support that persistent NAb positivity is associated withdisease activity in MS patients treated with IFN-β.
참고문헌 (27)
- The IFNB Multiple Sclerosis Study Group, "Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial", Neurology, 43, pp.655~661 (1993)[DOI]
- Deisenhammer F, "Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes", CNS Drugs, 23, pp.379~396 (2009)[DOI]
- Sorensen PS, "Appearance and disappearance of neutralizing antibodies during interferon-beta therapy", Neurology, 65, pp.33~39 (2005)[DOI]
- Rudick RA, "Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)", Neurology, 50, pp.1266~1272 (1998)[DOI]
- Francis GS, "Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS", Neurology, 65, pp.48~55 (2005)[DOI]
- Sorensen PS, "Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis", Lancet, 362, pp.1184~1191 (2003)[DOI]
- Hegen H, "Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development", Mult Scler, 20, pp.577~587 (2014)[DOI]
- Cepok S, "Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis", Arch Neurol, 66, pp.1216~1223 (2009)[DOI]
- Wingerchuk DM, "Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies", Mayo Clin Proc, 89, pp.225~240 (2014)[DOI]
- Rio J, "Predicting responders to therapies for multiple sclerosis", Nat Rev Neurol, 5, pp.553~560 (2009)[DOI]
- Rudick RA, "Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis", Lancet Neurol, 8, pp.545~559 (2009)[DOI]
- Polman CH, "Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria", Ann Neurol, 69, pp.292~302 (2011)[DOI]
- Hyun JW, "Utility of the rio score and modified rio score in Korean patients with multiple sclerosis", PLoS One, 10, pp.e0129243~ (2015)[DOI]
- Creeke PI, "Clinical testing for neutralizing antibodies to interferon-<TEX>${\beta}$<", TEX> in multiple sclerosis, 2013, pp.6, 3~17
- Govindappa K, "Development of interferon beta-neutralising antibodies in multiple sclerosis--a systematic review and meta-analysis", Eur J Clin Pharmacol, 71, pp.1287~1298 (2015)[DOI]
- Bertolotto A, "Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations", Immunopharmacology, 48, pp.95~100 (2000)[DOI]
- Pachner A, "MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity", Mol Diagn, 7, pp.17~25 (2003)
- Bertolotto A, "Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta", J Immunol Methods, 321, pp.19~31 (2007)[DOI]
- Farrell R, "Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of interferon-beta", Mult Scler, 14, pp.212~218 (2008)[DOI]
- Lam R, "Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients", J Immunol Methods, 336, pp.113~118 (2008)[DOI]
- Sorensen PS, "Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis", Eur J Neurol, 12, pp.817~827 (2005)[DOI]
- Polman CH, "Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis", Lancet Neurol, 9, pp.740~750 (2010)[DOI]
- Bertolotto A, "Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group", Neurol Sci, 35, pp.307~316 (2014)[DOI]
- Hesse D, "Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy", Eur J Neurol, 14, pp.850~859 (2007)[DOI]
- Goodin DS, "Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology", Neurology, 68, pp.977~984 (2007)[DOI]
- Buttmann M, "Interferon-beta induces transient systemic IP-10", CXCL10 chemokine release in patients with multiple sclerosis, 2004, pp.156, 195~203
- Lunemann JD, "Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto) antigen-specific T cells", J Immunol, 168, pp.4881~4888 (2002)[DOI]